MentionFox
Home › Executive changes › Praxis Precision Medicines, Inc.
Leadership changes · PRAX · SEC Form 8-K, Item 5.02

Leadership changes at Praxis Precision Medicines, Inc. (2026)

Before you join, sell to or invest in Praxis Precision Medicines, Inc.

MentionFox check on Praxis Precision Medicines, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/praxis-precision-medicines

Check Praxis Precision Medicines, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Praxis Precision Medicines, Inc.?

Who joined and who left Praxis Precision Medicines, Inc. (PRAX)? 1 appointment reported from 2026-01-08 to 2026-02-10, each cited to the company's own filing.

Jeffrey B. Kindler was appointed Director of Praxis Precision Medicines, Inc., effective January 8, 2026. As of November 14, 2026, Praxis Precision Medicines, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 8, 2026 to February 10, 2026, naming 1 appointment (Form 8-K, February 10, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Cormorant Asset Management, LP also filed stake reports on 17 other companies ↓

Sell to companies like Praxis Precision Medicines, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
In (appointed)1
Latest filing2026-02-10

Praxis Precision Medicines, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-08 to 2026-02-10. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Praxis Precision Medicines, Inc. files it.

Also on the record for Praxis Precision Medicines, Inc.

DateRecordFigureOur pageSource
November 5, 2026Stake report, Schedule 13G/A, by FMR LLC9.2% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by ORBIS INVESTMENT MANAGEMENT LTD5.5% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G, by Baker Bros. Advisors LP6.3% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by ORBIS INVESTMENT MANAGEMENT LTD8.9% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by Point72 Biotech Private Investments, LLC0.2% of the class5%+ stakesSource
May 6, 2026Stake report, Schedule 13G/A, by FMR LLC7.7% of the class5%+ stakesSource
April 30, 2026Stake report, Schedule 13G, by Vanguard Capital Management5.09% of the class5%+ stakesSource
March 27, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
February 17, 2026Stake report, Schedule 13G, by ORBIS INVESTMENT MANAGEMENT LTD5% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Perceptive Advisors LLC7.2% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Steven A. Cohen6.1% of the class5%+ stakesSource
February 12, 2026Stake report, Schedule 13G/A, by Adage Capital Management, L.P.3.83% of the class5%+ stakesSource

Selling to them or working with them? See who runs Praxis Precision Medicines, Inc. now and the warning signs.

Watch Praxis Precision Medicines, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Praxis Precision Medicines, Inc. and the records around it.

Praxis Precision Medicines, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Praxis Precision Medicines, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Praxis Precision Medicines, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Praxis Precision Medicines, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 26 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-10InDirector2026-01-088-K/A, 2026-02-10
2026-01-08Reportednot named in the filing8-K, 2026-01-08

Who leads Praxis Precision Medicines, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Praxis Precision Medicines, Inc.?

New leaders reset buying decisions — get the Full Report on Praxis Precision Medicines, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Praxis Precision Medicines, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Director at Praxis Precision Medicines, Inc., with the record behind each one.

Find candidates like Director at Praxis Precision Medicines, Inc.

Every change, in the filing's words

Filed 2026-02-10 · 8-K/A

Appointed: Jeffrey B. Kindler, Director, effective 2026-01-08

On January 8, 2026, Praxis Precision Medicines, Inc. (the "Company") filed a Current Report on Form 8-K (the "Initial 8-K") disclosing that the Board of Directors of the Company (the "Board") elected Jeffrey B. Kindler and Stuart A. Arbuckle to the Board, each as a Class II director, effective January 8, 2026.

Also stated in this filing

  • At the time of filing the Initial 8-K, the Board had not made a determination regarding any committee assignments for Mr. Kindler or Mr. Arbuckle.
Filed 2026-01-08 · 8-K

Reported

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Also stated in this filing

  • Appointment of Megan Sniecinski as Chief Operating Officer On January 8, 2026, Praxis Precision Medicines, Inc. (the "Company") announced the appointment of Megan Sniecinski as Chief Operating Officer of the Company, effective January 1, 2026 (the "Effective Date").
  • Ms. Sniecinski, age 45, served as Chief Business Officer of the Company from December 2021 through December 2025.
  • Prior to joining the Company, she served as chief business officer at BioCryst Pharmaceuticals from 2019 to 2021, overseeing corporate development, global medical affairs, program management and global supply chain.
  • From 2017 to 2019, she was senior vice president of business operations and program management at PTC Therapeutics, where she led established and grew the program management function and led business development during the company's transition toward becoming fully integrated, and commercial stage organization.
  • Before joining PTC, Ms. Sniecinski spent more than a decade at Merck serving in a diverse set of operational and strategic roles supporting their manufacturing operations, commercial and G&A divisions, with increasing responsibility, culminating as director of business development and strategic partnerships at Merck Vaccines.
  • Ms. Sniecinski received a B.S. in chemical engineering from the University of Virginia and an MBA from the Wharton School of the University of Pennsylvania.

Tools for this story

Each opens in a new tab, filled in for Praxis Precision Medicines, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/praxis-precision-medicines
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined Praxis Precision Medicines, Inc.? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/praxis-precision-medicines